Usefulness of PD-L1 evaluation using a large number of biopsy specimens for the prediction of nivolumab efficacy

Usefulness of PD-L1 evaluation using a large number of biopsy specimens for the prediction of nivolumab efficacy - Usefulness of PD-L1 evaluation using a large number of biopsy specimens for the prediction of nivolumab efficacy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030800

Enrollment

357

Registered

2018-01-14

Start date

2018-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Between Jan. 2016 and Aug. 2018, NSCLC patients recieved nivolumab at National Cancer Center Hospital East and National Cancer Center Hospital.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
The most suitable number of biopsy specimens for the prediction of nivolumab efficacy	—

Countries

Japan

Contacts

Public ContactHibiki Udagawa

National Cancer Center Hospital East Thoracic Oncology

hudagawa@east.ncc.go.jp04-7133-1111

Outcome results